文献速递甲状腺疾病糖尿病

Graves病与2型糖尿病风险:一项韩国人群基础研究

Graves' Disease and the Risk of Type 2 Diabetes: A Korean Population-Based Study.
PubMed 文献 · Thyroid · 2024-12-20

该回顾性人群研究利用韩国国民健康保险数据库,纳入36,243例Graves病患者和36,243例年龄性别匹配的对照,评估新诊断Graves病患者发生2型糖尿病的风险。结果显示Graves病患者糖尿病风险高于对照(HR=1.13,95%CI 1.06-1.21;5.1% vs 4.5%),诊断后前6个月风险最高(HR=3.21),抗甲状腺药物疗程更长和累积剂量更高与糖尿病风险增加相关。作者认为新诊断Graves病患者可考虑进行糖尿病筛查。

要点

  • Graves病患者2型糖尿病风险高于对照(HR=1.13,95%CI 1.06-1.21)。
  • Graves病诊断后前6个月糖尿病风险最高(HR=3.21)。
  • 抗甲状腺药物疗程更长和累积剂量更高与糖尿病风险增加相关。

核心结论

  • Graves病对新发2型糖尿病有负面影响,新诊断Graves病患者可考虑进行糖尿病筛查以促进早期发现和干预。

研究设计与样本

  • 回顾性人群基础研究,利用韩国国民健康保险数据库数据,纳入36,243例Graves病患者和36,243例年龄性别匹配的对照。

主要发现

  • Graves病患者糖尿病风险高于对照(HR=1.13,95%CI 1.06-1.21;5.1% vs 4.5%)。
  • Graves病诊断后前6个月风险最高(HR=3.21),6个月至2年期间风险显著(HR=1.36),诊断2年后与对照相当(HR=0.93)。
  • 抗甲状腺药物治疗疗程更长和累积剂量更高与糖尿病风险增加相关。
  • 2型糖尿病风险在不同治疗方式或临床结局间无差异,可能与各亚组患者数量少有关。

关键数值与推荐

  • 大多数患者(34,867例,96.2%)接受抗甲状腺药物治疗,其次为放射性碘治疗(1093例,3%)和手术(283例,0.8%)。

临床怎么用

  • 作者认为新诊断Graves病患者可考虑进行糖尿病筛查以促进早期发现和干预。

局限性

  • 2型糖尿病风险在不同治疗方式或临床结局间无差异,可能与各亚组患者数量少有关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Several meta-analyses have found no association between Graves' disease (GD) and an increased risk of incident diabetes; however, the intricate relationship between thyroid dysfunction and diabetes remains underexplored. In this study, we aimed to evaluate the risk of incident type 2 diabetes (T2DM) in a population newly diagnosed with GD, focusing on different treatment methods and treatment duration. Methods: This was a retrospective population-based study utilizing data from the Korean National Health Insurance database. We included 36,243 patients with GD and 36,243 controls, matched with age and sex. We calculated the incidence of T2DM among patients and controls based on treatment methods, such as medical therapy, radioactive iodine therapy (RAIT), and surgery. We examined the cumulative dose and duration of antithyroid drug (ATD) use for each patient. Results: The majority of patients (34,867, 96.2%) were treated with ATDs, followed by RAIT (1093 patients, 3%), and surgery (283 patients, 0.8%). After adjusting for age; sex; income; comorbidities, including hypertension, dyslipidemia, and cancer; body mass index; smoking; drinking; and exercise, patients with GD exhibited a higher risk of developing diabetes (hazard ratio [HR] = 1.13 [95% confidence interval 1.06-1.21]) than controls (5.1% vs. 4.5%, respectively). While the risk was the highest within the first six months after GD diagnosis (HR = 3.21), it was significant between six months and two years (HR = 1.36) and was comparable with the controls two years after GD diagnosis (HR = 0.93). A longer duration of ATD treatment and a higher cumulative dose were associated with an increased risk of diabetes. However, the risks for T2DM did not differ according to treatment modality or clinical outcomes, which was probably related to the small number of patients in each subgroup. Conclusions: Our findings highlight the negative impact of GD on the development of T2DM. Patients newly diagnosed with GD can be considered for diabetes screening to facilitate early detection and intervention.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Cho YY, Kim B, Jin SM, et al. Graves' Disease and the Risk of Type 2 Diabetes: A Korean Population-Based Study. Thyroid. 2024. PMID: 39705078. doi:10.1089/thy.2024.0270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。